Oxytrol Patch
Product Images NDC 0023-6153

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Oxytrol (NDC 0023-6153). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Allergan, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

The Structural Formula For Oxybutynin Is An Antispasmodic, Anticholinergic Agent. Oxybutynin Is Administered As A Racemate Of R- And S-isomers. Chemically, Oxybutynin Is D, L (racemic) 4-diethylamino-2-butynyl Phenylcyclohexylglycolate. The Empirical Formula Of Oxybutynin Is C22h31no3. (Oxytrol 01)

The Structural Formula For Oxybutynin Is An Antispasmodic, Anticholinergic Agent. Oxybutynin Is Administered As A Racemate Of R- And S-isomers. Chemically, Oxybutynin Is D, L (racemic) 4-diethylamino-2-butynyl Phenylcyclohexylglycolate. The Empirical Formula Of Oxybutynin Is C22h31no3. (Oxytrol 01)
FDA Label Image

Figure 1: Side And Top Views Of The Oxytrol System.(not To Scale) (Oxytrol 02)

Figure 1: Side And Top Views Of The Oxytrol System.(not To Scale) (Oxytrol 02)
FDA Label Image

Figure 2: Average Plasma Oxybutynin Concentrations (cp) In 24 Healthy Male And Female Volunteers During Single-dose Application Of Oxytrol 3.9 mg/day To The Abdomen, Buttock, And Hip (system Removal At 96 Hours). (Oxytrol 03)

Figure 2: Average Plasma Oxybutynin Concentrations (cp) In 24 Healthy Male And Female Volunteers During Single-dose Application Of Oxytrol 3.9 mg/day To The Abdomen, Buttock, And Hip (system Removal At 96 Hours). (Oxytrol 03)
FDA Label Image

Figure 3: Average (sem) Steady-state Oxybutynin And N-desethyloxybutynin Plasma Concentrations (cp) Measured In 13 Healthy Volunteers Following The Second Transdermal System Application In A Multiple-dose, Randomized, Crossover Study. (Oxytrol 04)

Figure 3: Average (sem) Steady-state Oxybutynin And N-desethyloxybutynin Plasma Concentrations (cp) Measured In 13 Healthy Volunteers Following The Second Transdermal System Application In A Multiple-dose, Randomized, Crossover Study. (Oxytrol 04)
FDA Label Image

Figure 4: Average Plasma Concentrations (cp) Measured After A Single, 96-hour Application Of The Oxytrol 3.9 mg/day System (aucinf/96) And A Single, 5 mg, Oral Immediate-release Dose Of Oxybutynin Chloride (aucinf/8) In 16 Healthy Male And Female Volunteers. (Oxytrol 05)

Figure 4: Average Plasma Concentrations (cp) Measured After A Single, 96-hour Application Of The Oxytrol 3.9 mg/day System (aucinf/96) And A Single, 5 mg, Oral Immediate-release Dose Of Oxybutynin Chloride (aucinf/8) In 16 Healthy Male And Female Volunteers. (Oxytrol 05)
FDA Label Image

· Do Not Use The Same Area For The Patch For At Least 1 Week. You May Choose To Try Different Sites When Using Oxytrol To Find The Sites That Are Most Comfortable For You And Where Clothing Will Not Rub Against It. (Oxytrol 06)

· Do Not Use The Same Area For The Patch For At Least 1 Week. You May Choose To Try Different Sites When Using Oxytrol To Find The Sites That Are Most Comfortable For You And Where Clothing Will Not Rub Against It. (Oxytrol 06)
FDA Label Image

· Each Patch Is Sealed In Its Own Protective Pouch. See Figure B.· When You Are Ready To Put On Your Oxytrol Patch, Tear Open The Pouch And Remove The Patch. See Figure C. (Oxytrol 07)

· Each Patch Is Sealed In Its Own Protective Pouch. See Figure B.· When You Are Ready To Put On Your Oxytrol Patch, Tear Open The Pouch And Remove The Patch. See Figure C. (Oxytrol 07)
FDA Label Image

· The Sticky Adhesive Side Of The Patch Is Covered By 2 Strips Of Overlapping Protective Liner. See Figure D.· Remove The First Piece Of The Protective Liner And Place The Patch, Adhesive Face Down, Firmly Onto The Skin. See Figure E. (Oxytrol 08)

· The Sticky Adhesive Side Of The Patch Is Covered By 2 Strips Of Overlapping Protective Liner. See Figure D.· Remove The First Piece Of The Protective Liner And Place The Patch, Adhesive Face Down, Firmly Onto The Skin. See Figure E. (Oxytrol 08)
FDA Label Image

· Bend The Patch In Half And Gently Roll The Remaining Part Onto Your Skin Using The Tips Of Your Fingers. As You Roll The Patch In Place, The Second Piece Of The Protective Liner Should Come Off The Patch. See Figure F.· Apply Firm Pressure Over The Surface Of The Patch With Your Fingers To Make Sure The Patch Stays On. See Figure G. (Oxytrol 09)

· Bend The Patch In Half And Gently Roll The Remaining Part Onto Your Skin Using The Tips Of Your Fingers. As You Roll The Patch In Place, The Second Piece Of The Protective Liner Should Come Off The Patch. See Figure F.· Apply Firm Pressure Over The Surface Of The Patch With Your Fingers To Make Sure The Patch Stays On. See Figure G. (Oxytrol 09)
FDA Label Image

Principal Display Paneloxytrol® (oxybutynin Transdermal System)ndc 0023-6153-083.9 mg/daycontains 8 Transdermal Systems (Oxytrol 0a)

Principal Display Paneloxytrol® (oxybutynin Transdermal System)ndc 0023-6153-083.9 mg/daycontains 8 Transdermal Systems (Oxytrol 0a)
OXYTROL is a medication that comes in a transdermal system form which contains oxybutynin as the active ingredient. It is prescribed through a prescription and the package and label contain important application instructions and should only be used as directed.*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.